INMED PHARMACEUTICALS INC. Increase (Decrease) in Deferred Revenue
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Deferred Revenue of $12.48 thousand for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2024-02-13
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2023-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was $471.00.
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was $15.70K.
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2023 was $16.17K.
- INMED PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2022 was -$5.14K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2023-12-31 | $12.48K 10-Q · filed 2024-02-13 | |||
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $0.00 derived: sum of 2 quarters · filed 2023-09-29 | $471.00 derived: sum of 3 quarters · filed 2024-02-13 | $16.17K 10-K · filed 2023-09-29 |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $471.00 derived: sum of 2 quarters · filed 2024-02-13 | $16.17K 10-Q · filed 2023-05-15 | $7.27K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-12-31 | $471.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $16.17K 10-Q · filed 2024-02-13 | $7.27K derived: sum of 3 quarters · filed 2024-02-13 | $7.78K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $15.70K 10-Q · filed 2023-11-14 | $6.80K derived: sum of 2 quarters · filed 2023-11-14 | $7.31K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$8.90K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | -$8.39K derived: sum of 2 quarters · filed 2023-09-29 | -$5.14K 10-K · filed 2023-09-29 | |
| 2022-03-31 | $512.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $3.76K 10-Q · filed 2023-05-15 | ||
| 2021-12-31 | $3.25K 10-Q · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |